Association of IFNL3 and IFNL4 polymorphisms with hepatitis C virus infection in a population from southeastern Brazil

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and associated complications such as liver cirrhosis and hepatocellular carcinoma (HCC). Viral and host factors are known to be predictors for antiviral therapy. Host factors that are predictors of sustained viral response (SVR) were discovered by genome-wide association studies (GWAS), including single-nucleotide polymorphisms (SNPs) in or near the interferon lambda gene (rs8099917, rs12979860 and rs368234815). The aim of the present study was to verify the genotype frequencies of SNPs rs8099917, rs12979860 and rs368234815 and to evaluate the association between SNPs and the outcome of HCV infection, taking into account the population ancestry. In this study, there was an association of the three polymorphisms with both clinical outcome and response to treatment with PEG-IFN and RBV. The polymorphisms rs12979860 and rs368234815 were associated with increased sensitivity (97.7 %, 95 % CI 87.2-100, and 93.3 %, 95 % CI 81.3-98.3; respectively) and with a greater predictive value of a positive response to treatment. In multivariable analysis adjusted by gender, age and ancestry, the haplotype G/T/Delta G was related to non-response to treatment (OR = 21.09, 95 % CI 5.33-83.51; p < 0.001) and to a higher chance of developing chronic infection (OR = 5.46, 95 % CI 2.06-14.46; p = 0.001) when compared to the haplotype T/C/TT. These findings may help to adjust our treatment policies for HCV infection based on greater certainty in studies with populations with such genetic characteristics, as well as allowing us to get to know the genetic profile of our population for these polymorphisms.

URI

https://observatorio.fm.usp.br/handle/OPI/14239

Referências

Tanaka Y, 2009, NAT GENET, V41, P1105, DOI 10.1038/ng.449
Manns M, 2011, ANTIVIR THER, V16, P1021, DOI 10.3851/IMP1894
Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309
Ramos JA, 2012, MEM I OSWALDO CRUZ, V107, P888, DOI 10.1590/S0074-02762012000700008
Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
Hamming OJ, 2013, EMBO J, V32, P3055, DOI 10.1038/emboj.2013.232
O'Brien TR, 2015, J HEPATOL, V63, P1103, DOI [10.1016/j.jhep.2015.06.035, 10.1016/j.jhep.2015.06]
Prokunina-Olsson L, 2013, NAT GENET, V45, P164, DOI 10.1038/ng.2521
Razavi H, 2014, J VIRAL HEPATITIS, V21, P34, DOI 10.1111/jvh.12248
Nelson DR, 2015, HEPATOLOGY, V61, P1127, DOI 10.1002/hep.27726
Thomas DL, 2009, NATURE, V461, P798, DOI 10.1038/nature08463
Esser C, 2005, J INVEST DERMATOL, V124, P1082, DOI 10.1111/j.0022-202X.2005.23709.x
Akamatsu S, 2015, J HEPATOL, V63, P554, DOI 10.1016/j.jhep.2015.03.033
Kowdley KV, 2013, LANCET, V381, P2100, DOI 10.1016/S0140-6736(13)60247-0
Lake SL, 2003, HUM HERED, V55, P56, DOI 10.1159/000071811
HOLM S, 1979, SCAND J STAT, V6, P65
Jouvin-Marche E, 2014, J INFECT DIS, V209, P1907, DOI 10.1093/infdis/jiu016
Olmedo DB, 2015, J MED VIROL, V87, P1702, DOI 10.1002/jmv.24227
Cavalcante LN, 2012, LIVER INT, V32, P476, DOI 10.1111/j.1478-3231.2011.02653.x
Manns MP, 2015, J VIRAL HEPATITIS, V22, P366, DOI 10.1111/jvh.12346
Tian C, 2008, HUM MOL GENET, V17, pR143, DOI 10.1093/hmg/ddn268
Suppiah V, 2009, NAT GENET, V41, P1100, DOI 10.1038/ng.447
Wack A, 2015, NAT IMMUNOL, V16, P802, DOI 10.1038/ni.3212
Gower E, 2014, J HEPATOL, V61, pS45, DOI 10.1016/j.jhep.2014.07.027
Santos NPC, 2010, HUM MUTAT, V31, P184, DOI 10.1002/humu.21159
Lawitz EJ, 2012, J HEPATOL, V57, P24, DOI 10.1016/j.jhep.2011.12.029
Gane EJ, 2013, ANTIMICROB AGENTS CH, V58, P1136
IBGE, 2015, EST POV
O'Brien TR, 2015, OPEN FORUM INFECT DI, V2
Terczynska-Dyla E, 2014, NAT COMMUN, V5

Coleções

Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - ODS/03

Página do item completo